Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inhibitor TherapeuticsINTI Earnings Yield (Joel Greenblatt) % is -19.65% as of Mar. 2026. The stock has 1 warning sign investors should review. Among 1,321 Biotechnology companies, Inhibitor Therapeutics ranks worse than 69.64% on this metric.
Inhibitor Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $17.53 Mil.
Inhibitor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.45 Mil. Inhibitor Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -19.65%.
The historical rank and industry rank for Inhibitor Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
INTI'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -27.4 Med: 0 Max: 0
Current: -27.4
INTI's Earnings Yield (Joel Greenblatt) % is ranked worse than 69.64% of 1321
companies
in the Biotechnology industry
Industry Median: -10.21
vs INTI: -27.40
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Inhibitor Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Inhibitor Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms
Inhibitor Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Inhibitor Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
INTI vs TPST, AKTX, ICU: Earnings Yield (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, Inhibitor Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibitor Therapeutics Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Inhibitor Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Inhibitor Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Inhibitor Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.45 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -19.65% mean?
Inhibitor Therapeutics (INTI) has a Earnings Yield (Joel Greenblatt) % of -19.65% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Inhibitor Therapeutics and its competitors. According to the industry distribution chart, Inhibitor Therapeutics ranks #920 out of 1321 companies in the Biotechnology industry, placing it in the top 69.6%.
Is Inhibitor Therapeutics' Earnings Yield (Joel Greenblatt) % too high?
Inhibitor Therapeutics' current Earnings Yield (Joel Greenblatt) % is -19.65%. Based on the distribution chart, Inhibitor Therapeutics ranks #920 out of 1321 companies in the Biotechnology industry, which is below the industry midpoint.
How does Inhibitor Therapeutics' Earnings Yield (Joel Greenblatt) % compare to TPST and AKTX?
According to the Biotechnology industry distribution chart, Inhibitor Therapeutics ranks #920 out of 1321 companies for Earnings Yield (Joel Greenblatt) %. This places Inhibitor Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Inhibitor Therapeutics and its competitors. Inhibitor Therapeutics's current Earnings Yield (Joel Greenblatt) % is -19.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibitor Therapeutics stock overvalued right now?
Inhibitor Therapeutics (INTI) has a current Earnings Yield (Joel Greenblatt) % of -19.65%. The current Earnings Yield (Joel Greenblatt) % is -19.65%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Inhibitor Therapeutics (INTI), the current Earnings Yield (Joel Greenblatt) % is -19.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and potentially commercializing therapeutics based on already approved active pharmaceutical ingredients, with a primary focus on basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. The Company develops therapeutics with patent-protected methods of use or delivery for certain cancers and non-cancerous proliferation disorders, and focuses on therapies for basal cell carcinoma (BCC) in the United States, utilizing itraconazole, an FDA-approved drug for fungal infections, with developed intellectual property and know-how related to the treatment of cancer patients using itraconazole.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INTI has been successfully added to your 
